<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27611598</article-id><article-id pub-id-type="pmc">5021017</article-id><article-id pub-id-type="doi">10.12659/MSM.897232</article-id><article-id pub-id-type="publisher-id">897232</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Correlation of Axial Spondyloarthritis with Anxiety and Depression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Qinghua</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-22-3202">A</xref><xref ref-type="author-notes" rid="fn3-medscimonit-22-3202">C</xref><xref ref-type="author-notes" rid="fn8-medscimonit-22-3202">*</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Yi</given-names></name><xref ref-type="author-notes" rid="fn4-medscimonit-22-3202">D</xref><xref ref-type="author-notes" rid="fn6-medscimonit-22-3202">F</xref><xref ref-type="author-notes" rid="fn8-medscimonit-22-3202">*</xref></contrib><contrib contrib-type="author"><name><surname>Mu</surname><given-names>Fangxiang</given-names></name><xref ref-type="author-notes" rid="fn4-medscimonit-22-3202">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-22-3202">E</xref></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Ying</given-names></name><xref ref-type="author-notes" rid="fn6-medscimonit-22-3202">F</xref><xref ref-type="author-notes" rid="fn7-medscimonit-22-3202">G</xref></contrib><contrib contrib-type="author"><name><surname>Fang</surname><given-names>Yongfei</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-22-3202">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-22-3202">B</xref><xref ref-type="corresp" rid="c1-medscimonit-22-3202"/></contrib><aff id="af1-medscimonit-22-3202">Department of Rheumatology, Southwest Hospital, Third Military Medical University, Chongqing, P.R. China</aff></contrib-group><author-notes><corresp id="c1-medscimonit-22-3202">Corresponding Author: Yongfei Fang, e-mail: <email>gjaowinrg@sina.com</email></corresp><fn id="fn1-medscimonit-22-3202"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-22-3202"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-22-3202"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-22-3202"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-22-3202"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-22-3202"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-22-3202"><label>G</label><p>Funds Collection</p></fn><fn id="fn8-medscimonit-22-3202"><label>*</label><p>Co-first authors; Qinghua Zou, Yi Jiang</p></fn></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>09</day><month>9</month><year>2016</year></pub-date><volume>22</volume><fpage>3202</fpage><lpage>3208</lpage><history><date date-type="received"><day>23</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>03</day><month>2</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Med Sci Monit, 2016</copyright-statement><copyright-year>2016</copyright-year><license><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</license-p></license></permissions><abstract><sec><title>Background</title><p>This study compared anxiety and depression in patients with nonradiographic axial spondyloarthritis (nr-axSpA) versus patients with ankylosing spondylitis (AS), and examined the relationship between clinical characteristics and psychological status.</p></sec><sec><title>Material/Methods</title><p>Patients diagnosed with axial spondyloarthritis (axSpA) were recruited for the study. Disease status was evaluated by the bath ankylosing spondylitis disease activity index (BASDAI), the bath ankylosing spondylitis functional index, visual analog scale, and the level of inflammatory markers. Psychological status was evaluated by the self-rating anxiety scale (SAS) and the self-rating depression scale (SDS).</p></sec><sec><title>Results</title><p>Sixty patients with axSpA were enrolled in the study, including 40 patients with AS and 20 patients with nr-axSpA. Patients with AS and patients with nr-axSpA had similar disease status and psychological status. Anxiety was significantly associated with disease status and SDS score (<italic>P</italic>&#x0003c;0.05 for all), whereas BASDAI (odds ratio [OR]=0.28, 95% CI=0.08&#x02013;0.97, <italic>P</italic>=0.045) and SDS (OR=0.90, 95% CI=0.82&#x02013;0.98, <italic>P</italic>=0.014) protected against anxiety. Depression was obviously correlated with smoking history, disease status, and SAS score (<italic>P</italic>&#x0003c;0.05 for all). Smoking history (OR=10.18, 95% CI=1.23&#x02013;84.23, <italic>P</italic>=0.031) and SAS score (OR=0.85, 95% CI=0.75&#x02013;0.97, <italic>P</italic>=0.014) were negatively correlated with risk of depression.</p></sec><sec><title>Conclusions</title><p>Patients with AS and patients with nr-axSpA had similar psychological status in terms of anxiety and depression. Disease status and smoking were significantly correlated with psychological status. Patients with higher SAS scores were more likely to have depression. The results of this study may be helpful to clinically guide psychological interventions for patients with axSpA.</p></sec></abstract><kwd-group><title>MeSH Keywords</title><kwd>Anxiety</kwd><kwd>Depression</kwd><kwd>Spondylitis, Ankylosing</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease characterized by chronic low back pain and primary involvement of the axial skeleton [<xref rid="b1-medscimonit-22-3202" ref-type="bibr">1</xref>,<xref rid="b2-medscimonit-22-3202" ref-type="bibr">2</xref>]. According to the classification criteria of the Assessment of Spondyloarthritis International Society (ASAS), the 2 major types of axSpA are nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) [<xref rid="b3-medscimonit-22-3202" ref-type="bibr">3</xref>]. Although not life-threatening, axSpA has adverse effects on the patient&#x02019;s quality of life and work productivity [<xref rid="b4-medscimonit-22-3202" ref-type="bibr">4</xref>,<xref rid="b5-medscimonit-22-3202" ref-type="bibr">5</xref>]. The disease onset is early adulthood, usually before age 45, and the disease may last for the rest of the patient&#x02019;s life. Patients with axSpA have a poor quality of life and reduced life expectancy, and there are no effective strategies for treatment [<xref rid="b6-medscimonit-22-3202" ref-type="bibr">6</xref>].</p><p>Recently, psychological disorders such as anxiety and depression have been frequently reported in patients with axSpA. Hakkou et al. reported that more than half of the patients with axSpA experienced depression or anxiety [<xref rid="b7-medscimonit-22-3202" ref-type="bibr">7</xref>]. The mechanism that leads to poor psychological status in patients with axSpA is not completely understood. The risk factors for the occurrence of anxiety and depression in patients with axSpA have been analyzed. A study conducted by Baysal et al. showed that disease activity and quality of life were risk factors for poor psychological status in patients with axSpA [<xref rid="b8-medscimonit-22-3202" ref-type="bibr">8</xref>]. A study conducted by Kilic et al. demonstrated that education level, disease activity, and quality of life were risk factors for anxiety and depression in patients with axSpA [<xref rid="b9-medscimonit-22-3202" ref-type="bibr">9</xref>]. However, the psychological status of patients in the AS group versus that of patients in the nr-axSpA group have rarely been compared in previous studies.</p><p>The purpose of the current study was to evaluate the risk factors for anxiety and depression in patients diagnosed with axSpA, including those with AS and nr-axSpA. The relationship between clinical characteristics and mood disorders (anxiety and depression) in patients with AS and nr-axSpA was analyzed. Multivariate logistic regression analysis was applied to determine the effects of patient characteristics on risk of anxiety or depression in the study population. The current study may be helpful in guiding psychological intervention, thus improving psychological status of patients with axSpA.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec sec-type="subjects"><title>Patients</title><p>Patients diagnosed with axSpA from April 2014 to May 2015 were recruited to the current study in the Southwest Hospital of Third Military Medical University, Chongqing, China. This study was approved by the ethics committee of that hospital.</p><p>Patients enrolled in the current study met the following criteria:</p><list list-type="order"><list-item><p>All patients were diagnosed with axSpA, according to the 2009 ASAS criteria [<xref rid="b10-medscimonit-22-3202" ref-type="bibr">10</xref>].</p></list-item><list-item><p>All patients were evaluated for evidence of radiographic sacroiliitis, based on the modified New York criteria.</p></list-item><list-item><p>All patients were age 18 years or older.</p></list-item></list><p>Patients with the following conditions were excluded from the study:</p><list list-type="order"><list-item><p>Another immune inflammatory disease.</p></list-item><list-item><p>Poor psychiatric history.</p></list-item><list-item><p>Use of psychotropic substances within 3 months.</p></list-item></list><p>All patients signed informed consent forms.</p><p>All assessments, including the anthropometric measurements, were done by the same physician. Clinical assessments, blood specimens, and questionnaires were done at the beginning of the study. Erythrocyte sedimentation rate (ESR) was detected by classic Westergren method (MicroSED-10<sup>&#x000ae;</sup> System, Electa Lab, Italy); turbidimetric inhibition immunoassay (QuikRead<sup>&#x000ae;</sup> 101 CRP analyzer, Orion Diagnostica Oy, Finland) was applied to investigate the level of C-reactive protein (CRP) in blood specimens. All of the testing progress were according to the manufacturers&#x02019; instructions.</p></sec><sec><title>Evaluation for diseases status</title><p>Disease activity was evaluated by the bath ankylosing spondylitis disease activity index (BASDAI) (0&#x02013;10, cut-off point 4) [<xref rid="b11-medscimonit-22-3202" ref-type="bibr">11</xref>]. The bath ankylosing spondylitis functional index (BASFI) (0&#x02013;10, cut-off point 2.1) was used to assess the functional status of the patients [<xref rid="b12-medscimonit-22-3202" ref-type="bibr">12</xref>]. The visual analog scale (VAS) was applied to pain intensity in patients (0&#x02013;10, cut-off point 3). We also evaluated ESR (cut-off points 15 mm/h for male and 20 mm/h for female), CRP (0.8&#x02013;8 mg/L in healthy people), AS disease activity score (ASDAS)-ESR, and ASDAS-CRP in patients diagnosed with axSpA.</p></sec><sec><title>Psychological status assessment</title><p>The psychological status of the recruited patients was evaluated according to the Zung self-rating anxiety scale (SAS) and self-rating depression scale (SDS) [<xref rid="b13-medscimonit-22-3202" ref-type="bibr">13</xref>,<xref rid="b14-medscimonit-22-3202" ref-type="bibr">14</xref>]. The SAS has 20 questions, with the scaled score range of 0 to 100. Patients whose SAS score was &#x0003e;50 were diagnosed with anxiety. The SDS has 20 questions, with the standard score range of 0 to 100. Patients whose SDS score was greater than the critical value of 53 were likely to have more severe symptoms.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>Statistical analysis was performed in SPSS 18.0 software. The continuous variables were shown as mean &#x000b1;SD, and analyzed by t test. Chi-square analysis was applied for dichotomous variables (i.e., qualitative data). Additionally, multivariate logistic regression analysis was used to detect the roles of depression or anxiety in patients diagnosed with axSpA. <italic>P</italic>&#x0003c;0.05 indicated significant difference.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro"><title>Demographic and clinical characteristics of the patient population</title><p>Sixty patients diagnosed with axSpA were enrolled in the current study. The patient population included 44 men and 16 women; average age was 31.77&#x000b1;10.11 years. A total of 40 patients were diagnosed with AS and 20 patients with nr-axSpA. The characteristics of the study subjects, including CRP and ESR levels and BASFI, BASDAI, VAS, ASDAS-CRP, ASDAS-ESR, SAS, and SDS results, are listed in <xref ref-type="table" rid="t1-medscimonit-22-3202">Table 1</xref>.</p></sec><sec sec-type="subjects"><title>Differences between patients with AS and patients with nr-axSpA</title><p>We compared baseline characteristics between patients with AS and patients with nr-axSpA. The results listed in <xref ref-type="table" rid="t1-medscimonit-22-3202">Table 1</xref> indicated that distributions of age, sex, and smoking history were similar between the AS and nr-axSpA groups (<italic>P</italic>&#x0003e;0.05 for all). Clinical characteristics, such as CRP and ESR levels and BASFI, BASDAI, VAS, ASDAS-CRP, and ASDAS-ESR results, were not associated with AS or nr-axSpA (<italic>P</italic>&#x0003e;0.05 for all). In addition, the burdens of anxiety and depression were similar between patients with AS and patients with nr-axSpA (<italic>P</italic>&#x0003e;0.05 for all).</p></sec><sec sec-type="intro"><title>Relationship between clinical characteristics and anxiety</title><p>We compared the clinical differences between patients with SAS score &#x02265;50 and patients SAS score &#x0003c;50. Twenty-four patients had SAS scores &#x0003e;50, and 36 had SAS scores &#x0003c;50. Comparison results indicated that BASFI (<italic>P</italic>=0.002), BASDAI (<italic>P</italic>=0.000), and SDS (<italic>P</italic>=0.000) were significantly associated with occurrence of anxiety in patients with axSpA. However, age; sex; smoking history; results of ASDAS-CRP, ASDAS-ESR, and VAS; and type of axSpA were not correlated with anxiety occurrence in patients with axSpA (<italic>P</italic>&#x0003e;0.05 for all; <xref ref-type="table" rid="t2-medscimonit-22-3202">Table 2</xref>).</p></sec><sec sec-type="intro"><title>Relationship between clinical characteristics and depression</title><p>Patients with SDS score over 53 were diagnosed with depression. In the present study, 26 patients were diagnosed with depression. Analysis results demonstrated that the incidence of depression in patients with axSpA was significantly correlated with smoking history (<italic>P</italic>=0.003), BASFI (<italic>P</italic>=0.005), BASDAI (<italic>P</italic>=0.000), and SAS score (<italic>P</italic>=0.000). Moreover, age; sex; results of ESR, CRP, ASDAS-CRP, ASDAS-ESR, and VAS; and type of axSpA were not significantly correlated with depression occurrence in patients with axSpA (<italic>P</italic>&#x0003e;0.05 for all; <xref ref-type="table" rid="t3-medscimonit-22-3202">Table 3</xref>).</p></sec><sec><title>Risk factors for anxiety and depression</title><p>Logistic regression analysis was applied for analysis of the relationship between AS characteristics and the risk of anxiety and depression in the study population. Analysis for anxiety risk indicated that SDS (OR=0.90, 95%CI=0.82&#x02013;0.98, <italic>P</italic>=0.014) and BASFI (OR=0.28, 95%CI=0.08&#x02013;0.97, <italic>P</italic>=0.045) were significantly associated with anxiety in patients with axSpA (<xref ref-type="table" rid="t4-medscimonit-22-3202">Table 4</xref>).</p><p>The results also showed that smoking history (OR=10.18, 95% CI=1.23&#x02013;84.23, <italic>P</italic>=0.031) and SAS score (OR=0.85, 95%CI=0.75&#x02013;0.97, <italic>P</italic>=0.014) were distinctly correlated with occurrence of depression in study population (<xref ref-type="table" rid="t5-medscimonit-22-3202">Table 5</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The current study was conducted to evaluate the differences in burden of anxiety and depression in patients diagnosed with axSpA, as well as the risk factors for anxiety and depression. Analysis of our results indicated that the incidence of anxiety and depression was similar between patients with AS and patients with nr-axSpA. BASFI, BASDAI, and SDS score were significantly correlated with burden of anxiety. The occurrence of depression was significantly associated with smoking history and BASFI, BASDAI, and SAS scores. We found that the clinical characteristics significantly were similar in the AS and nr-axSpA groups. This conclusion was different from those of previous studies. Indexes such as gender and CRP are different significantly between AS and nr-axSpA patients [<xref rid="b15-medscimonit-22-3202" ref-type="bibr">15</xref>&#x02013;<xref rid="b18-medscimonit-22-3202" ref-type="bibr">18</xref>]. This will need to be verified by more randomized controlled trials.</p><p>Anxiety and depression are common psychiatric abnormalities. Both disorders are treated with selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants [<xref rid="b19-medscimonit-22-3202" ref-type="bibr">19</xref>,<xref rid="b20-medscimonit-22-3202" ref-type="bibr">20</xref>]. These disorders and their treatment affect quality of life, especially for patients with comorbidities [<xref rid="b21-medscimonit-22-3202" ref-type="bibr">21</xref>&#x02013;<xref rid="b24-medscimonit-22-3202" ref-type="bibr">24</xref>]. Patients in both subgroups had back pain, which may cause both anxiety and depression. We found no significant difference between the SAS and SDS scores in the AS and axSpA groups. Compared with those in the AS group, patients in the nr-axSpA group had higher SAS scores and lower SDS scores; but all mean scores were lower than the cut-off points. These results indicated that the stages of anxiety and depression were not higher in patients with these disorders, and there was no significant difference between the 2 groups. In the stratified analysis, we proved that BASFI and BASDAI values were significantly correlated with burden of anxiety and depression in patients diagnosed with axSpA. Logistic regression showed that BASDAI was distinctly correlated with anxiety but not with depression. This conclusion is in accordance with the previous investigation. We also proved that patients with higher SAS scores were more likely to have lower SDS scores.</p><p>In the current study we found that smoking history was significantly correlated with, and a risk factor for, depression. Living habits may influence psychiatric status. A study by Hou et al. proved that a history of alcohol use was correlated with SAS and SDS scores in patients diagnosed with end-stage renal disease receiving maintenance hemodialysis [<xref rid="b25-medscimonit-22-3202" ref-type="bibr">25</xref>]. Rodriguez et al. proved that smoking cessation was related to a decrease in depressive symptoms, and relapse was related to an increase of such symptoms [<xref rid="b26-medscimonit-22-3202" ref-type="bibr">26</xref>]. Smoking status is positively correlated with depression and anxiety [<xref rid="b27-medscimonit-22-3202" ref-type="bibr">27</xref>&#x02013;<xref rid="b29-medscimonit-22-3202" ref-type="bibr">29</xref>]. Smoking cessation may be a useful way to prevent occurrence of anxiety and depression in patients with axSpA. However, a meta-analysis indicated that smoking had no significant association with the development of depression and anxiety [<xref rid="b30-medscimonit-22-3202" ref-type="bibr">30</xref>]. These results are inconsistent and differ from the results of the current study. These inconsistencies may be caused by different sample sizes, ethnicity, region of residence, or other factors. The small sample size of the current study might have led to different results regarding anxiety and depression.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Patients with AS and nr-axSpA had similar demographic and clinical characteristics. Both BASDAI and BASFI were significantly associated with the level of anxiety and depression in patients with axSpA; smoking was related to depression only in this population. BASDAI was significantly correlated with the development of anxiety but not with the development of depression. In addition, we found an obvious association between high SAS scores and risk of depression. This study may provide guidance for psychological intervention for patients with axSpA, thus helping to prevent the development of psychological disorders.</p><p>The present study has certain limitations. First, the small sample size might have contributed to the low test power of this study. Second, participants were all of the same race. Third, confounding factors were not considered in this study. Therefore, further studies should be carried out to confirm the present results.</p></sec></body><back><fn-group><fn id="fn9-medscimonit-22-3202"><p><bold>Disclosure statement</bold></p><p>None.</p></fn><fn id="fn10-medscimonit-22-3202"><p><bold>Source of support:</bold> Departmental sources</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-22-3202"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudwaleit</surname><given-names>M</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Landew&#x000e9;</surname><given-names>R</given-names></name><etal/></person-group><article-title>The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>70</volume><issue>1</issue><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">21109520</pub-id></element-citation></ref><ref id="b2-medscimonit-22-3202"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Hoeven</surname><given-names>L</given-names></name><name><surname>Vergouwe</surname><given-names>Y</given-names></name><name><surname>de Buck</surname><given-names>PD</given-names></name><etal/></person-group><article-title>External validation of a referral rule for axial spondyloarthritis in primary care patients with chronic low back pain</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>7</issue><fpage>e0131963</fpage><pub-id pub-id-type="pmid">26200904</pub-id></element-citation></ref><ref id="b3-medscimonit-22-3202"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudwaleit</surname><given-names>M</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Landew&#x000e9;</surname><given-names>R</given-names></name><etal/></person-group><article-title>The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection</article-title><source>Ann Rheum Dis</source><year>2009</year><volume>68</volume><issue>6</issue><fpage>777</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">19297344</pub-id></element-citation></ref><ref id="b4-medscimonit-22-3202"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelfer</surname><given-names>G</given-names></name><name><surname>Perry</surname><given-names>L</given-names></name><name><surname>Deodhar</surname><given-names>A</given-names></name></person-group><article-title>Golimumab for the treatment of axial spondyloarthritis</article-title><source>Expert Rev Clin Immunol</source><year>2016</year><volume>12</volume><issue>1</issue><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">26523483</pub-id></element-citation></ref><ref id="b5-medscimonit-22-3202"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martindale</surname><given-names>J</given-names></name><name><surname>Shukla</surname><given-names>R</given-names></name><name><surname>Goodacre</surname><given-names>J</given-names></name></person-group><article-title>The impact of ankylosing spondylitis/axial spondyloarthritis on work productivity</article-title><source>Best Pract Res Clin Rheumatol</source><year>2015</year><volume>29</volume><issue>3</issue><fpage>512</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">26612245</pub-id></element-citation></ref><ref id="b6-medscimonit-22-3202"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rios Rodriguez</surname><given-names>V</given-names></name><name><surname>Poddubnyy</surname><given-names>D</given-names></name></person-group><article-title>Old and new treatment targets in axial spondyloarthritis</article-title><source>RMD Open</source><year>2015</year><volume>1</volume><issue>Suppl 1</issue><fpage>e000054</fpage><pub-id pub-id-type="pmid">26557376</pub-id></element-citation></ref><ref id="b7-medscimonit-22-3202"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakkou</surname><given-names>J</given-names></name><name><surname>Rostom</surname><given-names>S</given-names></name><name><surname>Mengat</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sleep disturbance in Moroccan patients with ankylosing spondylitis: Prevalence and relationships with disease-specific variables, psychological status and quality of life</article-title><source>Rheumatol Int</source><year>2013</year><volume>33</volume><issue>2</issue><fpage>285</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">22441961</pub-id></element-citation></ref><ref id="b8-medscimonit-22-3202"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baysal</surname><given-names>O</given-names></name><name><surname>Durmu&#x0015f;</surname><given-names>B</given-names></name><name><surname>Ersoy</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis</article-title><source>Rheumatol Int</source><year>2011</year><volume>31</volume><issue>6</issue><fpage>795</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">20221605</pub-id></element-citation></ref><ref id="b9-medscimonit-22-3202"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilic</surname><given-names>G</given-names></name><name><surname>Kilic</surname><given-names>E</given-names></name><name><surname>Ozgocmen</surname><given-names>S</given-names></name></person-group><article-title>Relationship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis</article-title><source>Medicine (Baltimore)</source><year>2014</year><volume>93</volume><issue>29</issue><fpage>e337</fpage><pub-id pub-id-type="pmid">25546683</pub-id></element-citation></ref><ref id="b10-medscimonit-22-3202"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudwaleit</surname><given-names>M</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name></person-group><trans-title xml:lang="en">ASAS classification criteria for axial spondyloarthritis</trans-title><source>Z Rheumatol</source><year>2009</year><volume>68</volume><issue>7</issue><fpage>591</fpage><lpage>93</lpage><comment>[in German]</comment><pub-id pub-id-type="pmid">19680669</pub-id></element-citation></ref><ref id="b11-medscimonit-22-3202"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrett</surname><given-names>S</given-names></name><name><surname>Jenkinson</surname><given-names>T</given-names></name><name><surname>Kennedy</surname><given-names>LG</given-names></name><etal/></person-group><article-title>A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index</article-title><source>J Rheumatol</source><year>1994</year><volume>21</volume><issue>12</issue><fpage>2286</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">7699630</pub-id></element-citation></ref><ref id="b12-medscimonit-22-3202"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calin</surname><given-names>A</given-names></name><name><surname>Garrett</surname><given-names>S</given-names></name><name><surname>Whitelock</surname><given-names>H</given-names></name><etal/></person-group><article-title>A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index</article-title><source>J Rheumatol</source><year>1994</year><volume>21</volume><issue>12</issue><fpage>2281</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">7699629</pub-id></element-citation></ref><ref id="b13-medscimonit-22-3202"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zung</surname><given-names>WW</given-names></name></person-group><article-title>A rating instrument for anxiety disorders</article-title><source>Psychosomatics</source><year>1971</year><volume>12</volume><issue>6</issue><fpage>371</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">5172928</pub-id></element-citation></ref><ref id="b14-medscimonit-22-3202"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zung</surname><given-names>WW</given-names></name></person-group><article-title>A Self-Rating Depression Scale</article-title><source>Arch Gen Psychiatry</source><year>1965</year><volume>12</volume><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">14221692</pub-id></element-citation></ref><ref id="b15-medscimonit-22-3202"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiltz</surname><given-names>U</given-names></name><name><surname>Baraliakos</surname><given-names>X</given-names></name><name><surname>Karakostas</surname><given-names>P</given-names></name><etal/></person-group><article-title>Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?</article-title><source>Arthritis Care Res (Hoboken)</source><year>2012</year><volume>64</volume><issue>9</issue><fpage>1415</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">22505331</pub-id></element-citation></ref><ref id="b16-medscimonit-22-3202"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudwaleit</surname><given-names>M</given-names></name><name><surname>Haibel</surname><given-names>H</given-names></name><name><surname>Baraliakos</surname><given-names>X</given-names></name><etal/></person-group><article-title>The early disease stage in axial spondylarthritis: Results from the German Spondyloarthritis Inception Cohort</article-title><source>Arthritis Rheum</source><year>2009</year><volume>60</volume><issue>3</issue><fpage>717</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">19248087</pub-id></element-citation></ref><ref id="b17-medscimonit-22-3202"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>D</given-names></name><name><surname>Haroon</surname><given-names>N</given-names></name><name><surname>Ayearst</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ankylosing spondylitis and nonradiographic axial spondyloarthritis: Part of a common spectrum or distinct diseases?</article-title><source>J Rheumatol</source><year>2013</year><volume>40</volume><issue>12</issue><fpage>2038</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">24187102</pub-id></element-citation></ref><ref id="b18-medscimonit-22-3202"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Yoon</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Clinical characteristics of nonradiographic axial spondyloarthritis in Korea: A comparison with ankylosing spondylitis</article-title><source>Int J Rheum Dis</source><year>2015</year><volume>18</volume><issue>6</issue><fpage>661</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">25195726</pub-id></element-citation></ref><ref id="b19-medscimonit-22-3202"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>JM</given-names></name><name><surname>Daly</surname><given-names>E</given-names></name><name><surname>Kezic</surname><given-names>I</given-names></name><etal/></person-group><article-title>Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2016</year><volume>67</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">26804646</pub-id></element-citation></ref><ref id="b20-medscimonit-22-3202"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoonsari</surname><given-names>H</given-names></name><name><surname>Oghazian</surname><given-names>MB</given-names></name><name><surname>Kargar</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparing the efficacy of 8 weeks treatment of Cipram(R) and its generic citalopram in patients with Mixed Anxiety-Depressive Disorder</article-title><source>Iran J Psychiatry Behav Sci</source><year>2015</year><volume>9</volume><issue>2</issue><fpage>e230</fpage><pub-id pub-id-type="pmid">26288644</pub-id></element-citation></ref><ref id="b21-medscimonit-22-3202"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celano</surname><given-names>CM</given-names></name><name><surname>Millstein</surname><given-names>RA</given-names></name><name><surname>Bedoya</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis</article-title><source>Am Heart J</source><year>2015</year><volume>170</volume><issue>6</issue><fpage>1105</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">26678632</pub-id></element-citation></ref><ref id="b22-medscimonit-22-3202"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szak&#x000e1;ts</surname><given-names>I</given-names></name><name><surname>Sebesty&#x000e9;n</surname><given-names>M</given-names></name><name><surname>N&#x000e9;meth</surname><given-names>J</given-names></name><etal/></person-group><article-title>The role of health anxiety and depressive symptoms in dry eye disease</article-title><source>Curr Eye Res</source><year>2015</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="b23-medscimonit-22-3202"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karata&#x0015f;</surname><given-names>MB</given-names></name><name><surname>&#x0015e;ahan</surname><given-names>E</given-names></name><name><surname>&#x000d6;zcan</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Anxiety, depression, and general psychological distress in patients with coronary slow flow</article-title><source>Arq Bras Cardiol</source><year>2015</year><volume>105</volume><issue>4</issue><fpage>362</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">26559983</pub-id></element-citation></ref><ref id="b24-medscimonit-22-3202"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graczynska</surname><given-names>A</given-names></name><name><surname>Stefano</surname><given-names>GB</given-names></name></person-group><article-title>Depression: Evolutionary new neural circuitries are still adjusting for cognition</article-title><source>Med Sci Monit Basic Res</source><year>2015</year><volume>21</volume><fpage>213</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">26420361</pub-id></element-citation></ref><ref id="b25-medscimonit-22-3202"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Factors associated with depression and anxiety in patients with end-stage renal disease receiving maintenance hemodialysis</article-title><source>Int Urol Nephrol</source><year>2014</year><volume>46</volume><issue>8</issue><fpage>1645</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">24619584</pub-id></element-citation></ref><ref id="b26-medscimonit-22-3202"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Cano</surname><given-names>R</given-names></name><name><surname>L&#x000f3;pez-Dur&#x000e1;n</surname><given-names>A</given-names></name><name><surname>Del R&#x000ed;o</surname><given-names>EF</given-names></name><etal/></person-group><article-title>Smoking cessation and depressive symptoms at 1-, 3-, 6-, and 12-months follow-up</article-title><source>J Affect Disord</source><year>2015</year><volume>191</volume><fpage>94</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">26655118</pub-id></element-citation></ref><ref id="b27-medscimonit-22-3202"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandiera</surname><given-names>FC</given-names></name><name><surname>Arguelles</surname><given-names>W</given-names></name><name><surname>Gellman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cigarette smoking and depressive symptoms among Hispanic/Latino adults: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)</article-title><source>Nicotine Tob Res</source><year>2015</year><volume>17</volume><issue>6</issue><fpage>727</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">25332458</pub-id></element-citation></ref><ref id="b28-medscimonit-22-3202"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holma</surname><given-names>IA</given-names></name><name><surname>Holma</surname><given-names>KM</given-names></name><name><surname>Melartin</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Depression and smoking: A 5-year prospective study of patients with major depressive disorder</article-title><source>Depress Anxiety</source><year>2013</year><volume>30</volume><issue>6</issue><fpage>580</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">23606190</pub-id></element-citation></ref><ref id="b29-medscimonit-22-3202"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlina</surname><given-names>MM</given-names></name><name><surname>de Rondina</surname><given-names>RC</given-names></name><name><surname>Espinosa</surname><given-names>MM</given-names></name><name><surname>Botelho</surname><given-names>C</given-names></name></person-group><article-title>Depression, anxiety, stress, and motivation over the course of smoking cessation treatment</article-title><source>J Bras Pneumol</source><year>2015</year><volume>41</volume><issue>5</issue><fpage>433</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">26578135</pub-id></element-citation></ref><ref id="b30-medscimonit-22-3202"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>AE</given-names></name><name><surname>Fluharty</surname><given-names>ME</given-names></name><name><surname>Bj&#x000f8;rngaard</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Investigating the possible causal association of smoking with depression and anxiety using Mendelian randomisation meta-analysis: The CARTA consortium</article-title><source>BMJ Open</source><year>2014</year><volume>4</volume><issue>10</issue><fpage>e006141</fpage></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-medscimonit-22-3202" position="float"><label>Table 1</label><caption><p>Comparison for the demographic and clinical characteristics between AS and nr-axSpA group.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Features</th><th valign="bottom" align="center" rowspan="1" colspan="1">Total</th><th valign="bottom" align="center" rowspan="1" colspan="1">AS group (n=40)</th><th valign="bottom" align="center" rowspan="1" colspan="1">nr-axSpA group (n=20)</th><th valign="bottom" align="center" rowspan="1" colspan="1">&#x003c7;<sup>2</sup>/t</th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Age (mean &#x000b1;SD) (year)</td><td valign="middle" align="center" rowspan="1" colspan="1">31.77&#x000b1;10.11</td><td valign="middle" align="center" rowspan="1" colspan="1">31.48&#x000b1;10.13</td><td valign="middle" align="center" rowspan="1" colspan="1">32.36&#x000b1;10.29</td><td valign="middle" align="right" rowspan="1" colspan="1">0.343</td><td valign="middle" align="center" rowspan="1" colspan="1">0.755</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Gender</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="right" rowspan="1" colspan="1">0.628</td><td valign="middle" align="center" rowspan="1" colspan="1">0.409</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="middle" align="center" rowspan="1" colspan="1">44</td><td valign="middle" align="center" rowspan="1" colspan="1">28</td><td valign="middle" align="center" rowspan="1" colspan="1">16</td><td valign="middle" align="right" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="middle" align="center" rowspan="1" colspan="1">16</td><td valign="middle" align="center" rowspan="1" colspan="1">12</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="right" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Smoking history</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="right" rowspan="1" colspan="1">0.136</td><td valign="middle" align="center" rowspan="1" colspan="1">0.713</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">26</td><td valign="middle" align="center" rowspan="1" colspan="1">18</td><td valign="middle" align="center" rowspan="1" colspan="1">8</td><td valign="middle" align="right" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">34</td><td valign="middle" align="center" rowspan="1" colspan="1">22</td><td valign="middle" align="center" rowspan="1" colspan="1">12</td><td valign="middle" align="right" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ESR (mean &#x000b1;SD) (mm/h)</td><td valign="middle" align="center" rowspan="1" colspan="1">22.33&#x000b1;19.87</td><td valign="middle" align="center" rowspan="1" colspan="1">21.07&#x000b1;19.16</td><td valign="middle" align="center" rowspan="1" colspan="1">24.85&#x000b1;21.52</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;0.730</td><td valign="middle" align="center" rowspan="1" colspan="1">0.493</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CRP (mean &#x000b1;SD) (mg/L)</td><td valign="middle" align="center" rowspan="1" colspan="1">18.98&#x000b1;18.80</td><td valign="middle" align="center" rowspan="1" colspan="1">17.44&#x000b1;17.54</td><td valign="middle" align="center" rowspan="1" colspan="1">22.05&#x000b1;21.23</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;0.674</td><td valign="middle" align="center" rowspan="1" colspan="1">0.375</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BASFI (mean &#x000b1;SD)</td><td valign="middle" align="center" rowspan="1" colspan="1">1.98&#x000b1;1.98</td><td valign="middle" align="center" rowspan="1" colspan="1">1.75&#x000b1;1.90</td><td valign="middle" align="center" rowspan="1" colspan="1">2.44&#x000b1;2.11</td><td valign="middle" align="right" rowspan="1" colspan="1">1.231</td><td valign="middle" align="center" rowspan="1" colspan="1">0.204</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BASDAI (mean &#x000b1;SD)</td><td valign="middle" align="center" rowspan="1" colspan="1">3.38&#x000b1;1.90</td><td valign="middle" align="center" rowspan="1" colspan="1">3.24&#x000b1;2.00</td><td valign="middle" align="center" rowspan="1" colspan="1">3.67&#x000b1;1.69</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;0.964</td><td valign="middle" align="center" rowspan="1" colspan="1">0.409</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">VAS (mean &#x000b1;SD)</td><td valign="middle" align="center" rowspan="1" colspan="1">4.05&#x000b1;1.93</td><td valign="middle" align="center" rowspan="1" colspan="1">4.02&#x000b1;2.02</td><td valign="middle" align="center" rowspan="1" colspan="1">4.10&#x000b1;1.77</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;0.317</td><td valign="middle" align="center" rowspan="1" colspan="1">0.888</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ASDAS-CRP (mean &#x000b1;SD)</td><td valign="middle" align="center" rowspan="1" colspan="1">2.80&#x000b1;0.99</td><td valign="middle" align="center" rowspan="1" colspan="1">2.75&#x000b1;1.04</td><td valign="middle" align="center" rowspan="1" colspan="1">2.90&#x000b1;0.90</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;0.485</td><td valign="middle" align="center" rowspan="1" colspan="1">0.583</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ASDAS-ESR (mean &#x000b1;SD)</td><td valign="middle" align="center" rowspan="1" colspan="1">2.48&#x000b1;0.91</td><td valign="middle" align="center" rowspan="1" colspan="1">2.42&#x000b1;0.97</td><td valign="middle" align="center" rowspan="1" colspan="1">2.58&#x000b1;0.80</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;0.675</td><td valign="middle" align="center" rowspan="1" colspan="1">0.530</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">SAS (mean &#x000b1;SD)</td><td valign="middle" align="center" rowspan="1" colspan="1">45.82&#x000b1;9.62</td><td valign="middle" align="center" rowspan="1" colspan="1">44.25&#x000b1;9.41</td><td valign="middle" align="center" rowspan="1" colspan="1">48.95&#x000b1;9.48</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;1.831</td><td valign="middle" align="center" rowspan="1" colspan="1">0.074</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">SDS (mean &#x000b1;SD)</td><td valign="middle" align="center" rowspan="1" colspan="1">50.08&#x000b1;1.69</td><td valign="middle" align="center" rowspan="1" colspan="1">50.22&#x000b1;13.39</td><td valign="middle" align="center" rowspan="1" colspan="1">49.80&#x000b1;12.74</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;0.163</td><td valign="middle" align="center" rowspan="1" colspan="1">0.907</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-medscimonit-22-3202"><p><italic>P</italic> value, comparison between AS group and nr-axSpA group. Smoking, consumed more than one cigarette per day and last more than 6 months.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-medscimonit-22-3202" position="float"><label>Table 2</label><caption><p>Relationship between anxiety grade and clinical characteristics in patients diagnosed with axSpA.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Characteristics</th><th valign="bottom" align="center" rowspan="1" colspan="1">SAS &#x02265;50 (n=24)</th><th valign="bottom" align="center" rowspan="1" colspan="1">SAS &#x0003c;50 (n=36)</th><th valign="bottom" align="center" rowspan="1" colspan="1">&#x003c7;<sup>2</sup>/t</th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age</td><td valign="top" align="center" rowspan="1" colspan="1">32.08&#x000b1;11.06</td><td valign="top" align="center" rowspan="1" colspan="1">31.56&#x000b1;9.58</td><td valign="top" align="right" rowspan="1" colspan="1">0.199</td><td valign="top" align="center" rowspan="1" colspan="1">0.845</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="right" rowspan="1" colspan="1">0.696</td><td valign="top" align="center" rowspan="1" colspan="1">0.404</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="top" align="center" rowspan="1" colspan="1">19</td><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking history</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="right" rowspan="1" colspan="1">1.912</td><td valign="top" align="center" rowspan="1" colspan="1">0.167</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">23</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ESR (mm/h)</td><td valign="top" align="center" rowspan="1" colspan="1">19.58&#x000b1;16.33</td><td valign="top" align="center" rowspan="1" colspan="1">24.17&#x000b1;21.95</td><td valign="top" align="right" rowspan="1" colspan="1">0.871</td><td valign="top" align="center" rowspan="1" colspan="1">0.386</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CRP (mg/L)</td><td valign="top" align="center" rowspan="1" colspan="1">16.31&#x000b1;16.17</td><td valign="top" align="center" rowspan="1" colspan="1">20.75&#x000b1;20.38</td><td valign="top" align="right" rowspan="1" colspan="1">&#x02212;0.826</td><td valign="top" align="center" rowspan="1" colspan="1">0.375</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BASFI</td><td valign="top" align="center" rowspan="1" colspan="1">2.91&#x000b1;2.08</td><td valign="top" align="center" rowspan="1" colspan="1">1.36&#x000b1;1.67</td><td valign="top" align="right" rowspan="1" colspan="1">&#x02212;3.253</td><td valign="top" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BASDAI</td><td valign="top" align="center" rowspan="1" colspan="1">4.72&#x000b1;1.74</td><td valign="top" align="center" rowspan="1" colspan="1">2.49&#x000b1;1.45</td><td valign="top" align="right" rowspan="1" colspan="1">&#x02212;3.882</td><td valign="top" align="center" rowspan="1" colspan="1">0.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VAS</td><td valign="top" align="center" rowspan="1" colspan="1">4.29&#x000b1;1.97</td><td valign="top" align="center" rowspan="1" colspan="1">3.89&#x000b1;1.91</td><td valign="top" align="right" rowspan="1" colspan="1">&#x02212;0.851</td><td valign="top" align="center" rowspan="1" colspan="1">0.432</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ASDAS-CRP</td><td valign="top" align="center" rowspan="1" colspan="1">3.08&#x000b1;1.03</td><td valign="top" align="center" rowspan="1" colspan="1">2.62&#x000b1;0.93</td><td valign="top" align="right" rowspan="1" colspan="1">&#x02212;1.649</td><td valign="top" align="center" rowspan="1" colspan="1">0.075</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ASDAS-ESR</td><td valign="top" align="center" rowspan="1" colspan="1">2.73&#x000b1;0.92</td><td valign="top" align="center" rowspan="1" colspan="1">2.31&#x000b1;0.89</td><td valign="top" align="right" rowspan="1" colspan="1">&#x02212;1.729</td><td valign="top" align="center" rowspan="1" colspan="1">0.083</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SDS</td><td valign="top" align="center" rowspan="1" colspan="1">59.33&#x000b1;10.22</td><td valign="top" align="center" rowspan="1" colspan="1">43.92&#x000b1;11.02</td><td valign="top" align="right" rowspan="1" colspan="1">&#x02212;4.237</td><td valign="top" align="center" rowspan="1" colspan="1">0.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Types of axSpA</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="right" rowspan="1" colspan="1">1.250</td><td valign="top" align="center" rowspan="1" colspan="1">0.264</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;AS</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">26</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;nr-axSpA</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="t3-medscimonit-22-3202" position="float"><label>Table 3</label><caption><p>Association between depression grade and clinical features in patients with axSpA.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Characteristics</th><th valign="bottom" align="center" rowspan="1" colspan="1">SDS &#x02265;53 (n=26)</th><th valign="bottom" align="center" rowspan="1" colspan="1">SDS &#x0003c;53 (n=34)</th><th valign="bottom" align="center" rowspan="1" colspan="1">&#x003c7;<sup>2</sup>/t</th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Age</td><td valign="middle" align="center" rowspan="1" colspan="1">32.04&#x000b1;12.24</td><td valign="middle" align="center" rowspan="1" colspan="1">31.56&#x000b1;8.31</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;0.219</td><td valign="middle" align="center" rowspan="1" colspan="1">0.857</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Gender</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="right" rowspan="1" colspan="1">2.986</td><td valign="middle" align="center" rowspan="1" colspan="1">0.084</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="middle" align="center" rowspan="1" colspan="1">22</td><td valign="middle" align="center" rowspan="1" colspan="1">22</td><td valign="middle" align="right" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">12</td><td valign="middle" align="right" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Smoking history</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="right" rowspan="1" colspan="1">9.086</td><td valign="middle" align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">17</td><td valign="middle" align="center" rowspan="1" colspan="1">9</td><td valign="middle" align="right" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">9</td><td valign="middle" align="center" rowspan="1" colspan="1">25</td><td valign="middle" align="right" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ESR (mm/h)</td><td valign="middle" align="center" rowspan="1" colspan="1">20.65&#x000b1;16.19</td><td valign="middle" align="center" rowspan="1" colspan="1">23.62&#x000b1;22.44</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;0.523</td><td valign="middle" align="center" rowspan="1" colspan="1">0.571</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CRP (mg/L)</td><td valign="middle" align="center" rowspan="1" colspan="1">17.42&#x000b1;15.68</td><td valign="middle" align="center" rowspan="1" colspan="1">20.16&#x000b1;21.02</td><td valign="middle" align="right" rowspan="1" colspan="1">0.443</td><td valign="middle" align="center" rowspan="1" colspan="1">0.580</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BASFI</td><td valign="middle" align="center" rowspan="1" colspan="1">2.79&#x000b1;1.97</td><td valign="middle" align="center" rowspan="1" colspan="1">1.36&#x000b1;1.78</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;2.949</td><td valign="middle" align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BASDAI</td><td valign="middle" align="center" rowspan="1" colspan="1">4.44&#x000b1;1.82</td><td valign="middle" align="center" rowspan="1" colspan="1">2.58&#x000b1;1.55</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;4.205</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">VAS</td><td valign="middle" align="center" rowspan="1" colspan="1">4.42&#x000b1;1.90</td><td valign="middle" align="center" rowspan="1" colspan="1">3.76&#x000b1;1.92</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;1.321</td><td valign="middle" align="center" rowspan="1" colspan="1">0.192</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ASDAS-CRP</td><td valign="middle" align="center" rowspan="1" colspan="1">3.07&#x000b1;0.98</td><td valign="middle" align="center" rowspan="1" colspan="1">2.59&#x000b1;0.96</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;1.948</td><td valign="middle" align="center" rowspan="1" colspan="1">0.062</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ASDAS-ESR</td><td valign="middle" align="center" rowspan="1" colspan="1">2.73&#x000b1;0.93</td><td valign="middle" align="center" rowspan="1" colspan="1">2.29&#x000b1;0.87</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;1.807</td><td valign="middle" align="center" rowspan="1" colspan="1">0.065</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">SDS</td><td valign="middle" align="center" rowspan="1" colspan="1">52.08&#x000b1;8.46</td><td valign="middle" align="center" rowspan="1" colspan="1">41.03&#x000b1;7.53</td><td valign="middle" align="right" rowspan="1" colspan="1">&#x02212;3.552</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Types of axSpA</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="right" rowspan="1" colspan="1">0.034</td><td valign="middle" align="center" rowspan="1" colspan="1">0.854</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;AS</td><td valign="middle" align="center" rowspan="1" colspan="1">17</td><td valign="middle" align="center" rowspan="1" colspan="1">23</td><td valign="middle" align="right" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;nr-axSpA</td><td valign="middle" align="center" rowspan="1" colspan="1">9</td><td valign="middle" align="center" rowspan="1" colspan="1">11</td><td valign="middle" align="right" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="t4-medscimonit-22-3202" position="float"><label>Table 4</label><caption><p>Logistic analysis for the factors related anxiety risk in study subjects.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Factors</th><th valign="bottom" align="center" rowspan="1" colspan="1">OR</th><th valign="bottom" align="center" rowspan="1" colspan="1">95% CI</th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Gender</td><td valign="middle" align="center" rowspan="1" colspan="1">3.23</td><td valign="middle" align="right" rowspan="1" colspan="1">0.13&#x02013;82.54</td><td valign="middle" align="center" rowspan="1" colspan="1">0.479</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Age</td><td valign="middle" align="center" rowspan="1" colspan="1">1.03</td><td valign="middle" align="right" rowspan="1" colspan="1">0.92&#x02013;1.15</td><td valign="middle" align="center" rowspan="1" colspan="1">0.663</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Types of axSpA</td><td valign="middle" align="center" rowspan="1" colspan="1">0.42</td><td valign="middle" align="right" rowspan="1" colspan="1">0.61&#x02013;2.94</td><td valign="middle" align="center" rowspan="1" colspan="1">0.384</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Smoking history</td><td valign="middle" align="center" rowspan="1" colspan="1">0.56</td><td valign="middle" align="right" rowspan="1" colspan="1">0.052&#x02013;6.00</td><td valign="middle" align="center" rowspan="1" colspan="1">0.629</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ESR</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="right" rowspan="1" colspan="1">0.89&#x02013;1.13</td><td valign="middle" align="center" rowspan="1" colspan="1">0.945</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CRP</td><td valign="middle" align="center" rowspan="1" colspan="1">1.02</td><td valign="middle" align="right" rowspan="1" colspan="1">0.92&#x02013;1.13</td><td valign="middle" align="center" rowspan="1" colspan="1">0.760</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BASFI</td><td valign="middle" align="center" rowspan="1" colspan="1">0.80</td><td valign="middle" align="right" rowspan="1" colspan="1">0.36&#x02013;1.78</td><td valign="middle" align="center" rowspan="1" colspan="1">0.577</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BASDAI</td><td valign="middle" align="center" rowspan="1" colspan="1">0.28</td><td valign="middle" align="right" rowspan="1" colspan="1">0.08&#x02013;0.97</td><td valign="middle" align="center" rowspan="1" colspan="1">0.045</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">VAS</td><td valign="middle" align="center" rowspan="1" colspan="1">1.03</td><td valign="middle" align="right" rowspan="1" colspan="1">0.48&#x02013;2.22</td><td valign="middle" align="center" rowspan="1" colspan="1">0.937</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ASDAS-CRP</td><td valign="middle" align="center" rowspan="1" colspan="1">3.32</td><td valign="middle" align="right" rowspan="1" colspan="1">0.07&#x02013;158.03</td><td valign="middle" align="center" rowspan="1" colspan="1">0.542</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ASDAS-ESR</td><td valign="middle" align="center" rowspan="1" colspan="1">1.21</td><td valign="middle" align="right" rowspan="1" colspan="1">0.02&#x02013;64.01</td><td valign="middle" align="center" rowspan="1" colspan="1">0.926</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">SDS</td><td valign="middle" align="center" rowspan="1" colspan="1">0.90</td><td valign="middle" align="right" rowspan="1" colspan="1">0.82&#x02013;0.98</td><td valign="middle" align="center" rowspan="1" colspan="1">0.014</td></tr></tbody></table></table-wrap><table-wrap id="t5-medscimonit-22-3202" position="float"><label>Table 5</label><caption><p>Analysis for the risk factors of depression in patients diagnosed with axSpA.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Factors</th><th valign="bottom" align="center" rowspan="1" colspan="1">OR</th><th valign="bottom" align="center" rowspan="1" colspan="1">95% CI</th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Gender</td><td valign="middle" align="right" rowspan="1" colspan="1">15.96</td><td valign="middle" align="right" rowspan="1" colspan="1">0.86&#x02013;294.59</td><td valign="middle" align="center" rowspan="1" colspan="1">0.063</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Age</td><td valign="middle" align="right" rowspan="1" colspan="1">1.06</td><td valign="middle" align="right" rowspan="1" colspan="1">0.96&#x02013;1.17</td><td valign="middle" align="center" rowspan="1" colspan="1">0.241</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Types of axSpA</td><td valign="middle" align="right" rowspan="1" colspan="1">2.33</td><td valign="middle" align="right" rowspan="1" colspan="1">0.34&#x02013;15.82</td><td valign="middle" align="center" rowspan="1" colspan="1">0.286</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Smoking history</td><td valign="middle" align="right" rowspan="1" colspan="1">10.18</td><td valign="middle" align="right" rowspan="1" colspan="1">1.23&#x02013;84.23</td><td valign="middle" align="center" rowspan="1" colspan="1">0.031</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ESR</td><td valign="middle" align="right" rowspan="1" colspan="1">1.03</td><td valign="middle" align="right" rowspan="1" colspan="1">0.90&#x02013;1.18</td><td valign="middle" align="center" rowspan="1" colspan="1">0.687</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CRP</td><td valign="middle" align="right" rowspan="1" colspan="1">0.97</td><td valign="middle" align="right" rowspan="1" colspan="1">0.88&#x02013;1.08</td><td valign="middle" align="center" rowspan="1" colspan="1">0.640</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BASFI</td><td valign="middle" align="right" rowspan="1" colspan="1">0.86</td><td valign="middle" align="right" rowspan="1" colspan="1">0.44&#x02013;1.66</td><td valign="middle" align="center" rowspan="1" colspan="1">0.648</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BASDAI</td><td valign="middle" align="right" rowspan="1" colspan="1">0.49</td><td valign="middle" align="right" rowspan="1" colspan="1">0.15&#x02013;1.60</td><td valign="middle" align="center" rowspan="1" colspan="1">0.237</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">VAS</td><td valign="middle" align="right" rowspan="1" colspan="1">0.77</td><td valign="middle" align="right" rowspan="1" colspan="1">0.41&#x02013;1.48</td><td valign="middle" align="center" rowspan="1" colspan="1">0.437</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ASDAS-CRP</td><td valign="middle" align="right" rowspan="1" colspan="1">23.04</td><td valign="middle" align="right" rowspan="1" colspan="1">0.55&#x02013;969.03</td><td valign="middle" align="center" rowspan="1" colspan="1">0.100</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ASDAS-ESR</td><td valign="middle" align="right" rowspan="1" colspan="1">0.19</td><td valign="middle" align="right" rowspan="1" colspan="1">0.004&#x02013;8.80</td><td valign="middle" align="center" rowspan="1" colspan="1">0.394</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">SAS</td><td valign="middle" align="right" rowspan="1" colspan="1">0.85</td><td valign="middle" align="right" rowspan="1" colspan="1">0.74&#x02013;0.97</td><td valign="middle" align="center" rowspan="1" colspan="1">0.014</td></tr></tbody></table></table-wrap></floats-group></article>